Cordis and Bomaier Medical Forge Strategic Partnership to Commercialize Groundbreaking Vasecure Drug-Coated Balloon

Peripheral DCB has been widely used in the treatment of peripheral artery disease. Nowadays, peripheral drug-coated balloons have once again achieved innovative breakthroughs.

After years of dedicated research and development, BrosMed Medical has重磅 launched the Archaeopteryx Vasecure Drug-Coated Peripheral Balloon Dilatation Catheter, a global首创 featuringFull-length Protective SheathThe drug-coated balloon catheter, utilizing patented crystal and coating technology, successfully addresses the three major challenges of peripheral drug-coated balloons—shedding, loading, and retention—offering a novel solution for the treatment of peripheral diseases.

It is understood that currently, peripheral drug-coated balloons (DCBs) used in clinical applications have problems such as severe powder shedding, low drug-loading efficiency, and short retention time. Based on the structural characteristics of DCBs, whether hydrophilic or lipophilic excipients are used, it remains difficult to solve the issue of powder shedding during the processes of abrasion and blood flow flushing. This problem not only reduces the effective drug loading but also poses a risk of distal embolism. Additionally, the low drug-loading rate and insufficient drug retention time at the target site also lead to unstable efficacy. These factors limit the effectiveness of peripheral DCBs in broader clinical applications.

Arc'teryx Vasecure Drug-Coated Peripheral Balloon Dilatation Catheter adopts the world's first innovative technology withFull-length Protective SheathDelivery system, delivery processZero Powder Shedding, greatly reducing drug loss during the delivery process, minimizing distal vascular embolism caused by drug coating shedding, and enhancing the efficiency of drug transfer to the vascular wall.

In addition, a completely new"MicroCrystal Needle" Drug Crystal Design and Patented Spray Technology, adopting a brand-new embedded drug delivery model,Improve Reprint Efficiency, while ensuring the drug's effect on the blood vessel wall.Long-acting Retention。

Excellent product design has led to outstanding clinical outcomes, and the clinical trial data of the Archaeopteryx drug-coated balloon is encouraging. The late lumen loss (LLL) of target lesions at 6 months post-procedure was only 0.38, and the target lesion revascularization rate (TLR) at 6 months post-procedure was just 3.75%.

Currently, the product has been approved for marketing by the NMPA and is suitable for patients with superficial femoral artery (SFA) and popliteal artery (PPA) stenosis or occlusive lesions undergoing percutaneous transluminal angioplasty.

Cordis and BrosMed Medical, Two "Old Friends," Join Hands Again in a Powerful Collaboration to Advance the Commercial Application of the Archaeopteryx Vasecure Drug-Coated Peripheral Balloon Dilation Catheter!

After the signing of the aforementioned national general distribution agreement, Cordis will leverage its professional and well-established marketing network to help BrosMed Medical's Ancestor Bird Vasecure drug-coated peripheral balloon dilation catheter quickly penetrate the market.

At the same time, the signing of this agreement will also help Cordis further expand its peripheral intervention product line, fill the gap in its "drug-loaded era" of peripheral intervention products, and create a new business growth pole.